Literature Highlights - August 2022

Lilfilimab, CLE, cutaneous lupus erythematosus, anti-BDCA2, phase 2, anifrolumab, case series, SLICC/ACR DI, ethnicity, SLE, systemic lupus erythematosus, belimumab, calcineurin inhibitor, retrospective study, tacrolimus, SLE, SLICC, remission, LDA, damage accrual, adults, children, classification criteria, lupus nephritis, classification, class III/IV, patterns of injury, flare, PGA score, CLASI-A


LinkedIn